QR Pharma, Inc. Presents New Data on Posiphen in Down Syndrome at the Alzheimer’s Disease International Conference (AAIC 2017 London)

 

–Prevention or Treatment of Alzheimer’s disease in Down Syndrome through Translational Inhibition of Amyloid Precursor Protein (APP) —

 

Berwyn, Pa., July 11, 2017 — QR Pharma, Inc., a privately held phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s (AD), Parkinson’s (PD) and other neurodegenerative diseases, today announced the presentation at AAIC London of its data in Down Syndrome cells and mice. The talk is scheduled for Wednesday, July 19, 2017 at 8:30-9:00.

 

The presentation highlights studies conducted by investigators from The University of California in San Diego (Mobley Laboratory) and Los Angeles (John Laboratory) characterizing the effects of Posiphen in healthy versus diseased Down Syndrome cells and mice. Down syndrome has a triplication of chromosome 21 and chromosome 21 contains the APP gene; triplication of the APP gene results in high levels of APP. Posiphen lowers the levels of APP and its fragments and restores vesicle transport, neurotransmitter release and therefore may prevent or treat Alzheimer’s disease in Down syndrome and in Alzheimer’s patients in general.

 

“The observed development of Alzheimer’s disease in adults with Down Syndrome has been an area of increased study as the life expectancy of adults with Down Syndrome has extended.  The data generated in these studies demonstrates Posiphen’s ability to downregulate elevated APP levels in well understood in vitro and in vivo disease models of Down Syndrome.” noted Richard Fitzgerald, QR Pharma’s Chief Financial Officer.

 

“The data suggests that Posiphen should be tested in a preventive setting in Down syndrome individuals, as they carry a substantial risk of early onset of Alzheimer’s disease,” stated Dr. Claudine Bruck, Director of the Board of QR Pharma.

 

“These studies provide further confirmation of the neuroprotective effects of Posiphen,” stated Maria Maccecchini, Ph.D., President and CEO of QR Pharma.  “They add to a deep data set supporting the unique activity and potentially broad application of Posiphen in preventing as well as treating abnormal cellular environments and normalizing function.”

 

A full copy of the AAIC 2017 London talk entitled, “Reducing APP through Translational Inhibition can Prevent or Treat Alzheimer’s disease in Down Syndrome,” will be available by visiting the “Scientific Presentations” in the Press Room section of QR Pharma’s website at www.qrpharma.com.

 

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com

Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001
maccecchini@qrpharma.com
www.qrpharma.com